sparsentan will reduce the level or outcome of modafinil by impacting hepatic enzyme CYP2C19 metabolism. Use Warning/Keep track of. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy associated with these substrates. No withdrawal signs had been noticed in patients with modafinil treatment method cessation in https://modafinil77653.spintheblog.com/26484303/the-fact-about-modafinil-that-no-one-is-suggesting